TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3
Open Access
- 12 October 2009
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 147 (3), 347-351
- https://doi.org/10.1111/j.1365-2141.2009.07864.x
Abstract
Contrary to Total Therapy (TT) 2 for multiple myeloma patients, FGFR3− translocation bore no adverse effects on outcome in TT3 with added bortezomib. Del TP53, another poor-risk feature in TT2 and present in 10% of 441 patients treated, was examined for its prognostic consequences in TT3. Not affecting rate or duration of complete response, TP53 haplo-insufficiency also did not compromise, in the 83% with genomically defined low-risk myeloma, survival or event-free survival. FGFR3+ and FGFR3− molecular subgroups fared worse in the presence of del TP53 when applying TT2 but not TT3. Thus, the prognostic implications of del TP53 were protocol-, genome-defined risk- and molecular subgroup-dependent.Keywords
This publication has 12 references indexed in Scilit:
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaNew England Journal of Medicine, 2008
- Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2British Journal of Haematology, 2008
- Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation.Blood, 2007
- Proteasome Function Is Required for DNA Damage Response and Fanconi Anemia Pathway ActivationCancer Research, 2007
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1Blood, 2006
- Thalidomide and Hematopoietic-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2006
- Genetics and Cytogenetics of Multiple MyelomaCancer Research, 2004
- Treatment of multiple myelomaBlood, 2004
- The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsBlood, 2003
- Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridizationGenes, Chromosomes and Cancer, 1997